Clinical CDK2 Inhibitors: Trends to Selectivity and Efficacy.

Rusina, Polina V; Lisov, Alexey A; Denisova, Alexandra A; Gandalipov, Erik R; Novikov, Fedor N; Shtil, Alexander A

Rusina, Polina V; Lisov, Alexey A; Denisova, Alexandra A; Gandalipov, Erik R; Novikov, Fedor N; Shtil, Alexander A.

Afiliación

Rusina PV; Department of Chemistry, Lomonosov Moscow State University, 1/3 Leninskie Gory, 119991, Moscow, Russian Federation.
Lisov AA; Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 47 Leninsky Avenue, 119991, Moscow, Russian Federation.
Denisova AA; Department of Chemistry, Lomonosov Moscow State University, 1/3 Leninskie Gory, 119991, Moscow, Russian Federation.
Gandalipov ER; Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 47 Leninsky Avenue, 119991, Moscow, Russian Federation.
Novikov FN; Faculty of Bioengineering and Bioinformatics, Moscow State University, 1-73 Leninskie Gory, 119234, Moscow, Russian Federation.
Shtil AA; International Institute of Solution Chemistry and Advanced Materials Technologies, ITMO University, 9 Lomonosov Street, 191002, Saint-Petersburg, Russian Federation.

Recent Pat Anticancer Drug Discov ; 18(2): 102-107, 2022.

Article en En | MEDLINE | ID: mdl-35718977

Asunto(s)

Quinasa 2 Dependiente de la Ciclina; Humanos; Quinasa 2 Dependiente de la Ciclina/metabolismo; Fosforilación

Palabras clave

CDK2; cancer; catalytic domain.; clinical trials; inhibitors; serine-threonine protein kinase

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quinasa 2 Dependiente de la Ciclina Límite: Humans Idioma: En Revista: Recent Pat Anticancer Drug Discov Asunto de la revista: NEOPLASIAS / TERAPIA POR MEDICAMENTOS Año: 2022 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google